XTX Topco’s Recursion Pharmaceuticals RXRX Stock Holding History

XTX Topco’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44K	Sell	14,317 -33,591	-70%	-$130K	﹤0.01%	3355
2025 Q4	$196K	Buy	47,908 +24,421	+104%	+$121K	0.01%	2412
2025 Q3	$115K	Sell	23,487 -607,719	-96%	-$3.19M	0.01%	1996
2025 Q2	$3.19M	Buy	+631,206	New	+$3.1M	0.13%	171
2025 Q1	–	Sell	-83,547	Closed	-$565K	–	3004
2024 Q4	$565K	Buy	+83,547	New	+$562K	0.05%	668
2024 Q1	–	Sell	-15,349	Closed	-$151K	–	2256
2023 Q4	$151K	Buy	+15,349	New	+$109K	0.03%	1041
2023 Q2	–	Sell	-48,138	Closed	-$321K	–	1777
2023 Q1	$321K	Buy	48,138 +30,124	+167%	+$239K	0.07%	594
2022 Q4	$139K	Buy	18,014 +7,714	+75%	+$75.6K	0.03%	943
2022 Q3	$110K	Buy	+10,300	New	+$104K	0.03%	932

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

XTX Topco's RXRX Position: Q1 2026 in Review

XTX Topco reduced its Recursion Pharmaceuticals (RXRX) stake by 70% in Q1 2026, selling an estimated $130K and leaving 14,317 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #3355.

XTX Topco first reported a position in RXRX in Q3 2022 and has held it in 9 quarters since. The position peaked at $3.19M in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

XTX Topco held 14,317 shares of Recursion Pharmaceuticals worth $44K as of Q1 2026.
XTX Topco sold 33,591 Recursion Pharmaceuticals shares in Q1 2026, an estimated $130K.
Recursion Pharmaceuticals made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3355 holding.
XTX Topco first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
XTX Topco's Recursion Pharmaceuticals position peaked at $3.19M in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.